Last reviewed · How we verify

amoxicillin rifabutin — Competitive Intelligence Brief

amoxicillin rifabutin (amoxicillin rifabutin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antibiotic (beta-lactam + rifamycin). Area: Infectious Disease.

marketed Combination antibiotic (beta-lactam + rifamycin) Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

amoxicillin rifabutin (amoxicillin rifabutin) — Shanghai Jiao Tong University School of Medicine. This is a combination of two antibiotics: amoxicillin inhibits bacterial cell wall synthesis, while rifabutin inhibits bacterial RNA polymerase to suppress protein synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
amoxicillin rifabutin TARGET amoxicillin rifabutin Shanghai Jiao Tong University School of Medicine marketed Combination antibiotic (beta-lactam + rifamycin) Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antibiotic (beta-lactam + rifamycin) class)

  1. Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). amoxicillin rifabutin — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-rifabutin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: